Visiox Pharmaceuticals

Visiox Pharmaceuticals is a biopharmaceutical company founded in 2022 and headquartered in the United States. The company is dedicated to advancing the standard of care in ophthalmics by developing and commercializing therapeutic candidates for prevalent eye diseases lacking sufficient treatment options.

Under the slogan "Advancing the Standard of Care in Ophthalmics," Visiox is committed to disrupting and revolutionizing the market to maximize patient and physician satisfaction. The company aims to achieve this through close collaboration with eye care professionals.

Visiox's current pipeline includes two key assets. The first is PDP-716, a once-daily brimonidine designed for ocular hypertension and open-angle glaucoma. The second asset, SDN-037, is a twice-daily topical difluprednate targeting post-surgical inflammation and pain. Notably, both products employ a unique, patent-protected extended release technology, safeguarding their innovation until 2036.

Although specific details about the company's funding and investors are not currently available, Visiox Pharmaceuticals holds promise as a player in the biopharma, biotechnology, and healthcare industries, driving forward with a clear vision for addressing unmet needs in ophthalmic care.